Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Haisco Enters $140 Million Deal for Osteoarthritis Therapy

publication date: Sep 15, 2021

Haisco Pharmaceutical of Shannan in-licensed China rights to a novel osteoarthritis therapy from San Diego's Biosplice Therapeutics in a $140 million agreement. Lorecivivint, a potential disease-modifying osteoarthritis drug, is a CLK/DYRK kinase inhibitor that modulates the Wnt pathway. It is currently being tested in a US Phase III trial to treat knee osteoarthritis. Biosplice says it has the potential to be the first novel drug therapy for osteoarthritis in nearly 20 years. Haisco will make $20 million in upfront and near-term milestone payments. More details...

Stock Symbol: (SHZ: 002653)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.